• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Dazukibart is effective in reducing disease activity in adults with refractory dermatomyositis

byNeel MistryandTeddy Guo
February 12, 2025
in Chronic Disease, Dermatology, Rheumatology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. CDASI-A score at 12 weeks was significantly lower in dazukibart 600 mg versus placebo, suggesting reduced morbidity.

2. Treatment-related adverse events were comparable between all three groups.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Dermatomyositis is an autoimmune condition driven by type I interferon dysregulation. Current treatments fail to provide effective symptom control, highlighting the need for targeted therapies. This randomized controlled trial aimed to evaluate the efficacy and safety of dazukibart, a monoclonal antibody that neutralizes IFN-β, in adults with moderate-to-severe dermatomyositis. The primary outcome of this study was the change in Cutaneous Dermatomyositis Disease Area and Severity Index-Activity (CDASI-A) score at 12 weeks, while a key secondary outcome was safety. According to study results, dazukibart significantly reduced CDASI-A scores, demonstrating a pronounced improvement in disease activity. Although this study was well done, it was limited by a relatively small sample size.

Click to read the study in The Lancet

Relevant Reading: Trial of Intravenous Immune Globulin in Dermatomyositis

RELATED REPORTS

Nivolumab plus ipilimumab improves survival over lenvatinib or sorafenib in liver cancer

Upadacitinib with glucocorticoids superior to glucocorticoids alone for giant cell arteritis remission

2 Minute Medicine: Pharma Roundup – Perioperative Immunotherapy Efficacy, Expanded Prostate Cancer Indication, Rapid Subcutaneous Myeloma Administration, and Regulatory Compliance Findings [June 4 2025]

In-depth [randomized controlled trial]: Between Jan 23, 2018, and Feb 23, 2022, 125 patients were screened for eligibility across 25 university hospitals in Germany, Hungary, Poland, Spain, and the USA. Included were patients ≥ 18 years old with skin-predominant or muscle-predominant advanced dermatomyositis. Altogether, 75 patients (15 to dazukibart 150 mg, 37 to dazukibart 600 mg and 23 to placebo) were included in the final analysis. The primary outcome of CDASI-A score at 12 weeks was significantly lower in dazukibart 600 mg compared to placebo (mean change -19.2, 90% confidence interval [CI] -21.5 to -16.8, p<0.0001). The secondary outcome of safety revealed a similar incidence of treatment-emergent adverse events across groups (80% in dazukibart 150 mg, 81% in dazukibart 600 mg, and 78% in placebo). One death occurred in the dazukibart 600 mg group due to haemophagocytic lymphohistiocytosis. Overall, findings from this study suggest that dazukibart is a promising and well-tolerated option for advanced dermatomyositis.

Image: PD

©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: dazukibartdermatomyositisimmunotherapyinterferon betamonoclonal antibodyMyositisrheumatology
Previous Post

#VisualAbstract: Adjuvant Atezolizumab Does Not Provide Benefit in Early Triple-Negative Breast Cancer

Next Post

Polypharmacy associated with greater risk of mortality and hospitalizations in elderly

RelatedReports

Prognostic indicators for transarterial chemoembolization in patients with hepatocellular carcinoma with extrahepatic spread identified
AI Roundup

Nivolumab plus ipilimumab improves survival over lenvatinib or sorafenib in liver cancer

June 12, 2025
Study explores effects of daily iron supplementation in 2- to 5-year-olds
Chronic Disease

Upadacitinib with glucocorticoids superior to glucocorticoids alone for giant cell arteritis remission

June 9, 2025
2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]
Pharma

2 Minute Medicine: Pharma Roundup – Perioperative Immunotherapy Efficacy, Expanded Prostate Cancer Indication, Rapid Subcutaneous Myeloma Administration, and Regulatory Compliance Findings [June 4 2025]

June 4, 2025
Multidrug induction therapy increases remission from lupus nephritis
Chronic Disease

Obinutuzumab plus standard therapy is efficacious in managing active lupus nephritis

May 21, 2025
Next Post

Polypharmacy associated with greater risk of mortality and hospitalizations in elderly

#VisualAbstract: Liraglutide for 56 Weeks plus lifestyle interventions reduced BMI and Body Weight in Children with Obesity

#VisualAbstract: Iptacopan Reduced Proteinuria in Patients with IgA Nephropathy

Quick Take: Functional Outcome of Intravenous Thrombolysis in Patients With Lacunar Infarcts in the WAKE-UP Trial

Magnetic resonance imaging provides important information regarding infarct topography in determining stroke mechanism and risk

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Weighted vests and resistance training confer similar outcomes for bone density in the elderly
  • Breast cancer survivors may have a lower risk of Alzheimer’s dementia
  • Evaluating scar outcomes in pediatric burn patients following skin grafting 
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.